ADMA (STOCKS)
ADMA Biologics, Inc.
$8.500000
+0.290000 (+3.53%)
Prev close: $8.210000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Adam S. Grossman
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,970.07M
- Employees
- 685
- P/E (TTM)
- 12.11
- P/B (TTM)
- 4.89
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
6
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$0.19 | $0.20 | -0.0106 | -5.28% |
|
Dec 2025 (Q4)
|
$0.20 | $0.19 | +0.0113 | +5.99% |
|
Sep 2025 (Q3)
|
$0.15 | $0.15 | -0.0030 | -1.96% |
|
Jun 2025 (Q2)
|
$0.14 | $0.14 | -0.0028 | -1.96% |
Financial Statements
| Revenues | $509.86M |
| Benefits Costs and Expenses | $303.53M |
| Cost Of Revenue | $197.45M |
| Costs And Expenses | $303.53M |
| Gross Profit | $312.42M |
| Nonoperating Income/Loss | -$8.50M |
| Operating Expenses | $97.58M |
| Selling, General, and Administrative Expenses | $94.24M |
| Depreciation and Amortization | $7.97M |
| Research and Development | $6.53M |
| Operating Income/Loss | $214.84M |
| Income/Loss From Continuing Operations After Tax | $165.35M |
| Income/Loss From Continuing Operations Before Tax | $206.33M |
| Income Tax Expense/Benefit | $40.98M |
| Income Tax Expense/Benefit, Deferred | $10.89M |
| Net Income/Loss | $165.35M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $165.35M |
| Net Income/Loss Available To Common Stockholders, Basic | $165.35M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.69 |
| Diluted Earnings Per Share | $0.68 |
| Basic Average Shares | 716,057,426 |
| Diluted Average Shares | 732,641,791 |
| Assets | $665.18M |
| Current Assets | $511.17M |
| Inventory | $222.10M |
| Other Current Assets | $289.08M |
| Noncurrent Assets | $154.01M |
| Fixed Assets | $65.01M |
| Intangible Assets | $630.00K |
| Other Non-current Assets | $88.37M |
| Liabilities | $274.86M |
| Current Liabilities | $73.54M |
| Accounts Payable | $20.52M |
| Other Current Liabilities | $53.02M |
| Noncurrent Liabilities | $201.32M |
| Long-term Debt | $196.87M |
| Other Non-current Liabilities | $4.45M |
| Equity | $390.33M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $390.33M |
| Liabilities And Equity | $665.18M |
| Net Cash Flow From Operating Activities | $128.32M |
| Net Cash Flow From Operating Activities, Continuing | $128.32M |
| Net Cash Flow From Investing Activities | -$14.77M |
| Net Cash Flow From Investing Activities, Continuing | -$14.77M |
| Net Cash Flow From Financing Activities | -$47.03M |
| Net Cash Flow From Financing Activities, Continuing | -$47.03M |
| Net Cash Flow | $66.53M |
| Net Cash Flow, Continuing | $66.53M |
| Comprehensive Income/Loss | $165.35M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $165.35M |
| Other Comprehensive Income/Loss | $0.00 |